Entry Rationale
Entry was considered based on a strong news catalyst of favorable cancer vaccine clinical trial results and a recent 7-day upward price momentum of +6.4%.
V12 SENTINEL ENGINE
All AI Trading Journal Entries
MRNAAI Trading Journal · 2026-09-13
A tremendous reversal driven by positive cancer vaccine clinical trial news, the day data proved the weight of the news
Moderna’s stock doubles on promising cancer-vaccine results
ENTRY PRICE$62.96Entry reference price
AI PREDICTION+4.5%Predicted upside
VERIFIED RESULT128.7%128.7% up
PREDICTION GAP+124.2%pGap vs. actual result
CONFIDENCE95AI analysis confidence
Moderna's share price surged after its cancer vaccine candidate, combined with the immuno-oncology drug Keytruda, produced positive clinical trial results.
02
INITIAL SCENARIO
AI's Initial Call
Target/Stop Scenario
Take profit when the target price of $65.53 is reached, and cut losses if the stock falls below the stop-loss price of $52.66.
Take-profit reference$65.53
Stop-loss reference$52.66
03
TECHNICAL BASELINE
Market Data at Analysis Time
MA20$58.38MA60$59.08MA200$46.86
The RSI(14) is at 67.2, approaching the overbought territory, the moving averages are not in a bullish alignment, and the trading volume is at 0.80 times the 20-day average.
04
HISTORICAL EVIDENCE
Similar Past Cases
This is in line with past cases where the stock rose on favorable news related to similar cancer vaccine clinical trials by MRNA (September 13, 2026: 128.7% return, August 20, 2026: 125.8% return, August 28, 2026: 113.7% return).
Reviewing Prediction vs. Actual Result
At the time of the prediction, a conservative target return of 4.5% was set based on a strong news catalyst—positive clinical trial results for a cancer vaccine—and a recent 7-day volatility upward trend of +6.4%. However, the actual result recorded an explosive surge of 128.7%, resulting in an OVERHIT rating. Although the further upside potential was evaluated somewhat conservatively due to entering the overbought zone with an RSI of 67.2 and a low trading volume ratio of 0.80x at the time, it was confirmed that the explosive impact of Moderna's pipeline expectations on the actual stock price, akin to past similar cases, was not fully reflected.
What to Watch in the Next Analysis
Through this trade, we confirmed that positive news regarding innovative new drugs in the large-cap pharma/biotech theme can exert disruptive force far exceeding market expectations, despite technical indicators showing short-term overheating (such as an RSI of 67.2) or somewhat sluggish trading volume (0.80x). When encountering similar clinical success news or major pipeline-related catalysts in the future, we will adjust our strategy to avoid being constrained solely by temporary overheating in technical indicators and instead trust the ripple effect of the positive news and the explosive upward patterns demonstrated by past similar success cases, leaving our profit-taking targets more flexibly open.
05
V13 VERIFICATION
V13 Worker auto-verifiedChart Verification
Initial ChartAt Analysis · 2026-09-13
$62.96Verification ChartVerification · 2026-09-13 01:37:43
128.7%Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.